Login
$PYXS
$1.43 +$0.02 (1.34%) After hours

$PYXS 8-K SEC Filings

Filed On Filing
13 Nov 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Pyxis Oncology, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows:

05 Nov 2026 8-K: Results of Operations and Financial Condition

Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)

01 Oct 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Common Warrants to Purchase up to 49,310,352 Shares of Common Stock

09 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

08 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board

13 Aug 2026 8-K: Results of Operations and Financial Condition

Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap

02 Jul 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

Exhibit B – Form of Common Warrant Exhibit C – Form of Registration Rights Agreement

15 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 15, 2026, Pyxis Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders at 10:00 a.m. Eastern Daylight Time in a virtual format via live audio webcast (the “Annual Meeting”). As of April 20, 2026, the Company’s rec...

14 May 2026 8-K: Results of Operations and Financial Condition

Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a...

23 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026

06 Feb 2026 8-K: Financial Statements and Exhibits

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

18 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

03 Nov 2025 8-K: Results of Operations and Financial Condition

Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025

14 Aug 2025 8-K: Results of Operations and Financial Condition

Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of ...

04 Aug 2025 8-K: Other Events

On July 31, 2025, revisions to patient enrollment participants related to Pyxis Oncology, Inc.’s (the “Company”) Phase 1 monotherapy clinical trial to evaluate micvotabart pelidotin (“MICVO”, formerly PYX-201) were made available on Clin...

03 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

On July 1, 2025, Pamela Connealy, the Chief Financial Officer and Chief Operating Officer of Pyxis Oncology, Inc. (the “Company”),

18 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2025, Pyxis Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders at 09:00 a.m. Eastern Daylight Time in a virtual format via live audio webcast (the “Annual Meeting”). As of April 21, 2025, the Company’s rec...

15 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death

24 Mar 2025 8-K: Regulation FD Disclosure

Building a Differentiated ADC Company Nasdaq: PYXS ​ March 2025 Exhibit 99.1

18 Mar 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and metastatic head and nec...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support